Entrada Therapeutics Ownership | Who Owns Entrada Therapeutics?

Overview Forecast RevenueFinancials Chart

Entrada Therapeutics Ownership Summary

Entrada Therapeutics is owned by 74.09% institutional investors, 12.82% insiders, and 13.10% retail investors. Baker bros. advisors lp is the largest institutional shareholder, holding 14.53% of TRDA shares. T. Rowe Price New Horizons is the top mutual fund, with 5.22% of its assets in Entrada Therapeutics shares.

TRDA Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Entrada Therapeutics	74.09%	12.82%	13.10%
Sector	Healthcare Stocks	49.73%	8.84%	41.43%
Industry	Biotech Stocks	47.04%	8.74%	44.21%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Baker bros. advisors lp	4.87M	14.53%	$69.34M
Mpm asset management	4.43M	13.21%	$63.07M
5am venture management	4.41M	13.16%	$62.82M
Price t rowe associates inc /md/	3.13M	9.36%	$44.67M
Fmr	1.83M	5.46%	$26.07M
Blackrock	1.69M	5.06%	$24.14M
Janus henderson group	1.55M	4.63%	$22.11M
Vanguard group	1.13M	3.37%	$16.10M
Wellington management group llp	1.03M	3.09%	$14.73M
Stepstone group lp	761.28K	2.27%	$10.85M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Mpm asset management	4.43M	34.64%	$63.07M
5am venture management	4.41M	14.05%	$62.82M
Stepstone group lp	761.28K	2.20%	$10.85M
Baker bros. advisors lp	4.87M	0.89%	$69.34M
Tcg crossover management	584.96K	0.87%	$8.34M
Nan fung group	49.08K	0.75%	$699.42K
Corton capital	54.97K	0.41%	$783.37K
Moore capital management, lp	105.00K	0.03%	$1.50M
Gsa capital partners llp	21.29K	0.02%	$303.00K
Pdt partners	12.54K	0.02%	$178.67K

Top Buyers

Holder	Shares	% Assets	Change
Fmr	1.83M	0.00%	1.66M
Janus henderson group	1.55M	0.01%	1.55M
Price t rowe associates inc /md/	3.13M	0.01%	381.10K
Blackrock	1.69M	0.00%	207.70K
Jacobs levy equity management	134.24K	0.01%	134.24K

Top Sellers

Holder	Shares	% Assets	Change
Redmile group	-	-	-560.97K
Schonfeld strategic advisors	-	-	-81.41K
Morgan stanley	49.05K	0.00%	-58.51K
Citigroup	5.54K	0.00%	-50.74K
Winton group	-	-	-32.55K

New Positions

Holder	Shares	% Assets	Change	Value
Janus henderson group	1.55M	0.01%	1.55M	$22.11M
Jacobs levy equity management	134.24K	0.01%	134.24K	$1.91M
Renaissance	44.60K	0.00%	44.60K	$635.55K
Jane street group	26.75K	0.00%	26.75K	$381.25K
Gsa capital partners llp	21.29K	0.02%	21.29K	$303.00K

Sold Out

Holder	Change
Nelson, van denburg & campbell wealth management group	-4.00
Advantage alpha capital partners lp	-20.00
Plato investment management	-61.00
Metropolitan life insurance co/ny	-1.21K
New york state teachers retirement system	-1.92K

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Sep 30, 2024	101	21.69%	30,100,570	1.46%	74	0.98%	65	12.07%	18	63.64%
Jun 30, 2024	82	7.89%	29,668,719	13.99%	88	1.43%	58	61.11%	11	-52.17%
Mar 31, 2024	76	22.58%	26,027,444	-0.97%	78	1.26%	36	12.50%	23	64.29%
Dec 31, 2023	62	12.73%	26,281,950	0.95%	78	1.28%	32	39.13%	14	-
Sep 30, 2023	55	-1.79%	26,035,608	1.10%	78	1.24%	23	-32.35%	14	27.27%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
T. Rowe Price New Horizons	1.94M	5.22%	-76.04K
US Small-Cap Growth II Equity Comp	1.94M	5.22%	-76.85K
Vanguard Total Stock Mkt Idx Inv	686.72K	1.84%	9.31K
iShares Russell 2000 ETF	634.83K	1.70%	-1.43K
Fidelity Select Biotechnology	600.37K	1.61%	30.50K
Fidelity Growth Compy Commingled Pl S	564.26K	1.52%	3.08K
Fidelity Growth Compy Commingled Pl O	561.18K	1.51%	-
T. Rowe Price New Horizons Tr-Z	449.11K	1.21%	58.56K
Fidelity Growth Company Fund	357.80K	0.96%	-760.00
Vanguard Institutional Extnd Mkt Idx Tr	292.65K	0.78%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Dec 10, 2024	MPM BIOVENTURES 2018, L.P.	-	Sell	$476.36K
Dec 11, 2024	MPM BIOVENTURES 2018, L.P.	-	Sell	$440.75K
Dec 11, 2024	MPM BioVentures 2014, L.P.	-	Sell	$440.75K
Dec 10, 2024	MPM BioVentures 2014, L.P.	-	Sell	$476.36K
Nov 29, 2024	WENTWORTH KORY JAMES	Chief Financial Officer	Sell	$19.97K

Insider Transactions Trends

Date	Buy	Sell
2024 Q4	-	17
2024 Q3	-	13
2024 Q2	6	6
2024 Q1	7	4
2023 Q4	-	7

TRDA Ownership FAQ

Who Owns Entrada Therapeutics?

Entrada Therapeutics shareholders are primarily institutional investors at 74.09%, followed by 12.82% insiders and 13.09% retail investors. The average institutional ownership in Entrada Therapeutics's industry, Biotech Stocks , is 47.04%, which Entrada Therapeutics exceeds.

Who owns the most shares of Entrada Therapeutics?

Entrada Therapeutics’s largest shareholders are Baker bros. advisors lp (4.87M shares, 14.53%), Mpm asset management (4.43M shares, 13.21%), and 5am venture management (4.41M shares, 13.16%). Together, they hold 40.90% of Entrada Therapeutics’s total shares outstanding.

Does Blackrock own Entrada Therapeutics?

Yes, BlackRock owns 5.06% of Entrada Therapeutics, totaling 1.69M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 24.14M$. In the last quarter, BlackRock increased its holdings by 207.7K shares, a 13.98% change.

Who is Entrada Therapeutics’s biggest shareholder by percentage of total assets invested?

Mpm asset management is Entrada Therapeutics’s biggest shareholder by percentage of total assets invested, with 34.64% of its assets in 4.43M Entrada Therapeutics shares, valued at 63.07M$.

Who is the top mutual fund holder of Entrada Therapeutics shares?

T. Rowe Price New Horizons is the top mutual fund holder of Entrada Therapeutics shares, with 5.22% of its total shares outstanding invested in 1.94M Entrada Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools